This study will evaluate the impact of CYP3A4 induction on the single-dose pharmacokinetics of ALKS 5461.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Sublingual tablet given alone and in conjunction with Rifampin
Alkermes Investigational Site
Overland Park, Kansas, United States
AUCinf
Area under the concentration time curve from 0 to infinity of ALKS 5461 in the presence and absence of rifampin
Time frame: Up to 72 hours
AUClast
Area under the concentration time curve from time 0 to the last measurable timepoint in the presence and absence of rifampin
Time frame: Up to 72 hours
Cmax
Maximum plasma concentration in the presence and absence of rifampin.
Time frame: Up to 72 hours
Safety and tolerability will be measured by the incidence of Adverse Events
Time frame: UP to 27 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.